TP53 and cancer: Indeed, Tan et al., 2015 [9] demonstrated that the mutation occurring at residue p53-R273H (a contact mutant), but not the conformational mutant p53-R175H, promotes cancer cell survival and resistance to cell death (anoikis) of the cancer cell via constitutively activating PI3K/AKT signaling.